ADMA Biologics Inc - Company Profile
Powered by 
All the sales intelligence you need on ADMA Biologics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ADMA Biologics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ADMA Biologics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ADMA Biologics Inc (ADMA Biologics) is a biopharmaceutical company. It develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company's product portfolio includes Bivigam, an Intravenous Immune Globulin (IVIG) product for the treatment of Primary Immunodeficiency Disease (PIDD), Asceniv, an IVIG product for the treatment of PIDD in adults and adolescents and Nabi-HB, for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg) and other listed exposures to Hepatitis B. It also operates plasma collection facilities that carry out plasma collection and offer blood plasma to manufacture the products, and has a manufacturing facility in Boca Raton, Florida. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.
Headquarters
United States of America
Address
465 State Route 17, Ramsey, New Jersey, 07446
Website
www.admabiologics.com
Telephone
1 201 4785552
No of Employees
647
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADMA (NASD)
Revenue (2024)
$510.2M
19.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-25.7%
(2024 vs 2023)
Market Cap*
$1.9B
Net Profit Margin (2024)
XYZ
-37.9%
(2024 vs 2023)
* As of and is in US$
ADMA Biologics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Asceniv: Primary Immunodeficiency Disease (PIDD) | Asceniv |
| Bivigam: Primary Immunodeficiency Disease (PIDD) | Bivigam |
| Nabi-HB: Acute exposure to blood containing Hepatitis B surface antigen, and other listed exposures to Hepatitis B | Nabi-HB |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In December, the company agreed to divest three plasma centers for US$12 million. |
| 2025 | Contracts/Agreements | In October, the company entered into a distribution agreement with McKesson Specialty for ASCENIV and BIVIGAM. |
| 2024 | Regulatory Approval | In March, the company received FDA approvals of extended room temperature storage conditions for Asceniv and Bivigam. |
Competitor Comparison
| Key Parameters | ADMA Biologics Inc | Takeda Pharmaceutical Co Ltd | Grifols SA | Octapharma AG | Kedrion SpA |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | Spain | Switzerland | Italy |
| City | Ramsey | Chuo-Ku | Sant Cugat Del Valles | Lachen | Lucca |
| State/Province | New Jersey | Tokyo | Barcelona | Schwyz | Toscana |
| No. of Employees | 647 | 47,455 | 23,822 | 11,141 | 5,000 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steven A. Elms | Chairman | Executive Board | 2007 | 62 |
| Adam S. Grossman | President; Chief Executive Officer; Director | Executive Board | 2011 | 49 |
| Terry Kohler | Chief Financial Officer; Treasurer | Senior Management | 2026 | - |
| Kaitlin Kestenberg | Senior Vice President - Compliance; Chief Operating Officer | Senior Management | 2024 | 39 |
| Jerrold B. Grossman | Vice Chairman | Executive Board | 2007 | 78 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer